Why product longevity will change the treatment landscape post-lockdown

By Sinclair / 10 Jun 2020

Longer lasting treatments will take on a new importance for patients and practitioners alike, as HA and Botulinum Toxin injectable treatments have worn off during homestay, suggest aesthetic experts Dr Victoria Manning and Dr Charlotte Woodward, founders of the award winning River Aesthetics.

“We receive the best feedback from our patients following treatments which offer the greatest longevity. They tend to have the most impact over a longer period of time and our patients prioritise them because they look better for longer between appointments and they are more cost effective in the long term”, say Dr Manning and Dr Woodward.

They continue: “We already have a long waiting list when our clinics reopen after lockdown, and treatments which offer longevity are, by far, our most requested. This includes Silhouette Soft thread lifts and biostimulating injectables, such as Ellansé, both of which encourages the proliferation of natural collagen production over a period of three-four months. Our patients who had one of those treatments pre-lockdown have told us that their facial volume, and the elasticity of their skin, as well as its quality, are all better now than before Covid-19, due to the presence of fresh new collagen.”

A longer term lasting treatment such as Ellansé may also be preferable as clinics continue to implement social distancing measures. The procedure doesn’t need to be repeated for three years, compared with HA fillers and Botulinum Toxin which lasts between six months to a year. As a result, it minimises contact between patient and practitioner, making the most of valuable face to face contact.

Studies conducted by Dr Pierre Nicolau have confirmed that new collagen type 1 endures 20 months after injection with Ellansé. Ellansé has 3 products in the range: S, M & L, which offer longevity ranging from 18 months to 3 years.

Leading dentist and aesthetic expert Dr MJ Rowland-Warmann concurs: “With Ellansé I always find that my patients want treatment before they need it. Compare this with HA fillers, which are much more prone to biologic factors in their performance and degradation pattern, patients often need treatment before they want it (or were financially ready for it again).”

A product with more longevity doesn’t just improve patients’ skin health, it also plays an important role in the profit of a clinic. “As Ellansé lasts so much longer than an HA filler, we can charge about £50-£100 more per ml for the treatment, while the demand on our time is the same”, say Dr Manning and Dr Woodward.

Patients treated with Ellansé can realistically expect to experience immediate increased facial volumisation, to improve the appearance of folds, lines and wrinkles, as well as initiate scar repair, post-injection. Volumisation continues to develop for up to four months, as microspheres in the filler gel encourage the body to produce Type 1 collagen in response. However, it is the longevity of the results Ellansé achieves its strong differentiating factor.

The collagen stimulation is brought about by a bio-absorbable medical polymer called PolyCaproLactone. When micro-spheres made from this polymer, suspended in the filler gel, are absorbed by the body, this triggers a reaction which results in the body generating its own repair collagen.

Ellansé is comprised of a unique and patented composition – 70% Carboxymethyl Cellulose (CMC) based gel carrier and 30% PolyCaproLactone (PCL) microspheres. The length of the polymer chain of the PCL is what gives Ellansé its unique longevity properties last from 18 months to three years. The greater the length of the polymer chain, the longer lasting the product will be.

Dr Rowland-Warmann concludes: “I love Ellansé for the simple fact it has such a phenomenal longevity and predictability. Selecting it gives me the confidence of knowing that when I see my patients at their review - be it six or nine months down the line - I will see the great results that I had planned for them at the outset.”

For more information, visit https://www.sinclairpharma.com/ellanse